2007•Journal watchRequires access

Metabolic Effects of Initial PI-Sparing Antiretroviral Therapy

Keith Henry

Abstract

Initial reports of metabolic dysfunction among HIV-infected patients on potent combination antiretroviral therapy focused on the role of PIs, but later reports described a more complex situation, with NRTIs and NNRTIs also having metabolic effects. Now, investigators have analyzed data from ACTG 5095 to determine the metabolic aspects of three initial PI-sparing regimens: AZT/3TC/abacavir, efavirenz + AZT/3TC, and efavirenz + AZT/3TC/abacavir. Previous results from this large …

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Efavirenz, Abacavir, Medicine, Antiretroviral therapy, Human immunodeficiency virus (HIV), Antiretroviral drug, Pharmacology, Zidovudine